What is HC Wainwright’s Estimate for AVBP FY2026 Earnings?

ArriVent BioPharma, Inc. (NASDAQ:AVBP) – HC Wainwright raised their FY2026 earnings per share estimates for ArriVent BioPharma in a research report issued on Tuesday, November 10th. HC Wainwright analyst R. Burns now forecasts that the company will post earnings of ($3.73) per share for the year, up from their previous estimate of ($4.06). HC Wainwright has a “Buy” rating and a $27.00 price objective on the stock. The consensus estimate for ArriVent BioPharma’s current full-year earnings is ($4.04) per share. HC Wainwright also issued estimates for ArriVent BioPharma’s Q4 2026 earnings at ($0.90) EPS, Q1 2027 earnings at ($0.92) EPS, Q2 2027 earnings at ($0.94) EPS, Q3 2027 earnings at ($0.96) EPS, Q4 2027 earnings at ($0.98) EPS and FY2027 earnings at ($3.80) EPS.

ArriVent BioPharma (NASDAQ:AVBP) last issued its quarterly earnings results on Monday, November 9th. The company reported ($0.81) EPS for the quarter, topping analysts’ consensus estimates of ($1.05) by $0.24. The company had revenue of $5.00 million during the quarter, compared to analysts’ expectations of $0.80 million.

Several other equities research analysts have also issued reports on AVBP. Weiss Ratings reissued a “sell (d-)” rating on shares of ArriVent BioPharma in a report on Thursday, October 15th. Guggenheim lifted their price target on shares of ArriVent BioPharma from $18.00 to $30.00 and gave the company a “buy” rating in a report on Tuesday, October 27th. Citigroup dropped their price target on shares of ArriVent BioPharma from $40.00 to $20.00 and set a “buy” rating for the company in a research report on Wednesday, October 7th. Cantor Fitzgerald reissued an “overweight” rating on shares of ArriVent BioPharma in a research note on Tuesday, September 22nd. Finally, BTIG Research restated a “buy” rating and set a $29.00 price objective on shares of ArriVent BioPharma in a research report on Friday, October 16th. Nine analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, ArriVent BioPharma has an average rating of “Moderate Buy” and a consensus price target of $24.89.

ArriVent BioPharma Trading Up 0.1%

Shares of NASDAQ:AVBP opened at $13.51 on Thursday. The stock has a 50 day moving average of $22.07 and a 200 day moving average of $26.51. The company has a market cap of $698.78 million, a PE ratio of -3.75 and a beta of 1.66. ArriVent BioPharma has a 12-month low of $11.36 and a 12-month high of $35.83.

Institutional Trading of ArriVent BioPharma

Several institutional investors have recently made changes to their positions in AVBP. Alps Advisors Inc. raised its stake in ArriVent BioPharma by 38.7% during the 3rd quarter. Alps Advisors Inc. now owns 65,315 shares of the company’s stock valued at $1,978,000 after purchasing an additional 18,241 shares during the period. Mirae Asset Global Investments Co. Ltd. purchased a new position in ArriVent BioPharma in the 3rd quarter worth approximately $76,000. Profund Advisors LLC boosted its stake in ArriVent BioPharma by 12.8% in the 3rd quarter. Profund Advisors LLC now owns 14,257 shares of the company’s stock worth $432,000 after purchasing an additional 1,614 shares during the period. China Universal Asset Management Co. Ltd. boosted its stake in ArriVent BioPharma by 21.4% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 8,997 shares of the company’s stock worth $266,000 after purchasing an additional 1,585 shares during the period. Finally, Moody Aldrich Partners LLC boosted its stake in ArriVent BioPharma by 4.1% in the 3rd quarter. Moody Aldrich Partners LLC now owns 45,852 shares of the company’s stock worth $1,388,000 after purchasing an additional 1,808 shares during the period. Hedge funds and other institutional investors own 9.48% of the company’s stock.

About ArriVent BioPharma

ArriVent BioPharma is a clinical-stage biopharmaceutical company focused on developing medicines for people with cancer. The company advances therapies intended to address significant unmet medical needs, with an emphasis on treatments that may offer new options for patients with difficult-to-treat tumors. Its lead clinical program is furmonertinib, an oral targeted therapy being studied for non-small cell lung cancer with certain epidermal growth factor receptor (EGFR) mutations, including exon 20 insertion mutations.